August 2023 Recap of Drug Updates

The summary below gives an overview of important additions and changes MPR has made to its drug database through the end of August. The chart below provides highlights of key monograph updates made this month (not an inclusive list).

Click on the name of the drugs to view the full monographs on eMPR.com.

Key: D=Dosing, IND=Indication, ITX=Interactions, CI=Contraindications,
W/P=Warnings/Precautions, ADR=Adverse Reactions,
HS=How Supplied, MFR=Manufacturer Change

DRUG NAME	UPDATES
(Click on drug name to go to MPR monograph.)	IND	D	CON	W/P	ITX	ADR	HS	MFR
AMJEVITA (Adalimumab-atto)	X	X					X
ILARIS (Canakinumab)	X	X				X
INGREZZA (Valbenazine)	X	X		X		X	X
INVOKANA (Canagliflozin)	X	X	X	X
INVOKAMET (Canagliflozin, metformin [as HCl] ext-rel)	X	X	X	X
LEQEMBI (Lecanemab-irmb)				X	X	X
LONSURF (Trifluridine, tipiracil)	X	X		X
NESINA (Alogliptin)				X		X
ZEPZELCA (Lurbinectedin)		X			X
ZETIA (Ezetimibe)	X	X	X	X	X	X

Review more drug monograph updates